MX2022007904A - Composiciones y usos de polipeptidos cationicos, sinteticos, antimicrobianos localmente aplicados con seguridad y desempe?o mejorados. - Google Patents

Composiciones y usos de polipeptidos cationicos, sinteticos, antimicrobianos localmente aplicados con seguridad y desempe?o mejorados.

Info

Publication number
MX2022007904A
MX2022007904A MX2022007904A MX2022007904A MX2022007904A MX 2022007904 A MX2022007904 A MX 2022007904A MX 2022007904 A MX2022007904 A MX 2022007904A MX 2022007904 A MX2022007904 A MX 2022007904A MX 2022007904 A MX2022007904 A MX 2022007904A
Authority
MX
Mexico
Prior art keywords
antimicrobial
pharmaceutical composition
compositions
safety
aqueous carrier
Prior art date
Application number
MX2022007904A
Other languages
English (en)
Inventor
Michael P Bevilacqua
Daniel J Huang
Doug Looker
Original Assignee
Amicrobe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicrobe Inc filed Critical Amicrobe Inc
Publication of MX2022007904A publication Critical patent/MX2022007904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se formulan composiciones farmacéuticas antimicrobianas para permitir aplicación local in vivo de dosis que proporcionan eficacia antimicrobiana con bajo riesgo de toxicidades de tejido local y/o bajo riesgo de toxicidades sistémicas/distantes de órganos. En diferentes modalidades las composiciones farmacéuticas antimicrobianas comprenden polipéptidos catiónicos, sintéticos, antimicrobianos que se dispersan en un portador acuoso y se formulan para lograr un grado deseado de auto-montaje y/o viscosidad de composición.
MX2022007904A 2017-04-06 2019-10-03 Composiciones y usos de polipeptidos cationicos, sinteticos, antimicrobianos localmente aplicados con seguridad y desempe?o mejorados. MX2022007904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482630P 2017-04-06 2017-04-06

Publications (1)

Publication Number Publication Date
MX2022007904A true MX2022007904A (es) 2022-07-21

Family

ID=63712780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007904A MX2022007904A (es) 2017-04-06 2019-10-03 Composiciones y usos de polipeptidos cationicos, sinteticos, antimicrobianos localmente aplicados con seguridad y desempe?o mejorados.

Country Status (12)

Country Link
US (2) US11285189B2 (es)
EP (1) EP3606543A4 (es)
JP (2) JP2020513016A (es)
KR (1) KR20200018400A (es)
CN (1) CN110740744A (es)
AU (2) AU2018249552A1 (es)
BR (1) BR112019020781A2 (es)
CA (1) CA3058901A1 (es)
MX (1) MX2022007904A (es)
RU (1) RU2019133628A (es)
SG (1) SG11201909016TA (es)
WO (1) WO2018187617A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6224069B2 (ja) 2012-03-23 2017-11-01 アミクローブ，インコーポレイテッド 組織適合特性を有する抗菌剤の組成物および使用
RU2019133628A (ru) 2017-04-06 2021-05-06 Амикроб, Инк. Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью
EP4055029A4 (en) 2019-11-08 2023-11-22 University of Pittsburgh - of the Commonwealth System of Higher Education COMPOSITIONS COMPRISING ANTIMICROBIAL PEPTIDES
CN115397454A (zh) * 2020-03-31 2022-11-25 立美基股份有限公司 通过辐照对自组装肽进行灭菌
CA3179706A1 (en) * 2020-04-08 2021-10-14 Amicrobe, Inc. Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6680365B1 (en) 1998-03-19 2004-01-20 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
DK1322287T3 (da) 2000-09-28 2006-07-24 Chiron Corp Mikropartikler til administration af heterologe nukleinsyrer
US6835536B2 (en) * 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
JP2003171463A (ja) * 2001-12-06 2003-06-20 Chisso Corp ポリリジン及びその製造法
WO2003067311A1 (fr) 2002-02-07 2003-08-14 Ophtecs Corporation Solution pour lentilles de contact
US20050004002A1 (en) 2002-12-09 2005-01-06 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
EP1644382B1 (en) 2003-07-11 2008-03-05 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
JP5015604B2 (ja) 2003-12-30 2012-08-29 バイオアクティブ ポリマーズ アクティエボラーグ 曝露された生物組織の表面保護
EP1722819B1 (en) * 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
JP5020078B2 (ja) 2004-08-18 2012-09-05 ノバビオティクス・リミテッド ペプチド
CN101189256B (zh) 2005-06-06 2014-05-21 诺维信阿德宁生物技术公司 具有抗微生物活性的多肽和编码该多肽的多核苷酸
US20080139450A1 (en) 2005-07-01 2008-06-12 Srinivasa Madhyastha Antimicrobial Compositions and Uses Thereof
US20070190110A1 (en) 2006-02-10 2007-08-16 Pameijer Cornelis H Agents and devices for providing blood clotting functions to wounds
WO2008070571A2 (en) 2006-12-01 2008-06-12 The Regents Of The University Of California Vesicles of self-assembling block copolymers and methods for making and using the same
CA2691645A1 (en) 2007-06-25 2008-12-31 Lipopeptide Ab New medical products
EP2192923A2 (en) 2007-08-27 2010-06-09 Massachusetts Institute of Technology Bi-functional polymer-attached inhibitors of influenza virus
US20110098344A1 (en) 2008-06-19 2011-04-28 Nippon Shinyaku Co., Ltd. Drug carrier
EP2349310B1 (en) 2008-10-20 2014-07-23 Moerae Matrix, Inc. Polypeptide for treating or preventing adhesions
JP5752051B2 (ja) 2009-01-23 2015-07-22 ケーン バイオテク インコーポレーテッド バイオフィルム除去用抗菌性組成物およびその使用
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
BR112012026880B1 (pt) 2010-04-27 2021-03-16 Lysando Ag método para eliminação ou redução de um biofilme bacteriano, variante de endolisina ou variante de bacteriocina e seus usos
ES2622498T3 (es) 2010-08-23 2017-07-06 The Regents Of The University Of California Composiciones y usos de materiales con actividad antimicrobiana elevada y toxicidad baja
CN103370087A (zh) * 2011-01-19 2013-10-23 目立康株式会社 隐形眼镜用液体制剂
US9781949B2 (en) 2011-03-31 2017-10-10 The University Of Massachusetts Antimicrobial delivery systems, methods of manufacture, and methods of use thereof
JP6224069B2 (ja) * 2012-03-23 2017-11-01 アミクローブ，インコーポレイテッド 組織適合特性を有する抗菌剤の組成物および使用
DE102014101663A1 (de) 2014-02-11 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthetische artifizielle Peptide mit antimikrobieller Wirkung
EP3194422B1 (en) 2014-09-19 2020-04-29 Tensive Controls, Inc. Anti-microbial peptides
AU2015338969B2 (en) * 2014-10-30 2020-08-27 Biomet Manufacturing, Llc Methods of preventing surgical site infections
JP2016113373A (ja) * 2014-12-11 2016-06-23 エスポ化学株式会社 抗菌性、抗ウイルス性を有する水溶性組成物
RU2019133628A (ru) 2017-04-06 2021-05-06 Амикроб, Инк. Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью
JP2021514985A (ja) 2018-03-02 2021-06-17 ジャニュアリー セラピューティクス，インク． ナノ粒子組成物

Also Published As

Publication number Publication date
CN110740744A (zh) 2020-01-31
EP3606543A1 (en) 2020-02-12
US20210100867A1 (en) 2021-04-08
WO2018187617A1 (en) 2018-10-11
US11285189B2 (en) 2022-03-29
KR20200018400A (ko) 2020-02-19
RU2019133628A3 (es) 2021-07-14
JP2020513016A (ja) 2020-04-30
JP2023054375A (ja) 2023-04-13
CA3058901A1 (en) 2018-10-11
WO2018187617A8 (en) 2019-10-17
SG11201909016TA (en) 2019-10-30
AU2023202283A1 (en) 2023-05-11
RU2019133628A (ru) 2021-05-06
BR112019020781A2 (pt) 2020-04-28
EP3606543A4 (en) 2020-12-16
US20230017994A1 (en) 2023-01-19
AU2018249552A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2022007904A (es) Composiciones y usos de polipeptidos cationicos, sinteticos, antimicrobianos localmente aplicados con seguridad y desempe?o mejorados.
NZ730564A (en) Composition and kits for inhibition of pathogenic microbial infection and methods of using the same
EP3318128A3 (en) Composition comprising a biological control agent and a fungicide
MX2013011314A (es) Tratamientos oftalmicos.
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
HK1119934A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ725994A (en) Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
NZ742941A (en) Composition comprising a biological control agent and a fungicide selected from inhibitors of the mitosis and cell division or compounds having a multi-site action
BR112012025390B8 (pt) Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112016017897A8 (pt) uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
BR112022002289A2 (pt) Composições de curativo líquido e seus usos veterinários
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
BRPI0408827A (pt) composições oftálmicas preservadas
EP4166156A4 (en) COMPOSITION FOR THE PREVENTION, MITIGATION OR TREATMENT OF ALLERGIC DISEASES OR PRURITUS WITH PENTAPEPTIDE AS THE ACTIVE INGREDIENT
BRPI0418380A (pt) composição de agressina-bioimune para a supressão de infecções por xantomonas em safras de agricultura
MX2013004260A (es) Uso de deposito de fosfolipidos viscosos estables en almacenamiento para tratar heridas.
EP3698801A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES, WITH ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC MEDICINAL PRODUCT AS THE ACTIVE SUBSTANCES
FR2967062B1 (fr) Utilisation d'extrait de grenade pour prevenir et/ou traiter les poches perioculaires
MX2017015129A (es) Composicion y usos de la misma.
MX2017008145A (es) Composiciones para el cuidado personal con activo de fosfato de zinc.
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite